AREG

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland, July 10, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
Monday, July 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland  , July 9, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting

Retrieved on: 
Monday, October 18, 2021
Gastric lavage, EMA, Exo, Cell, Microsoft, NTFS, LPS, Sev Ohanian, Amphiregulin, California Institute for Regenerative Medicine, Respiratory disease, European Medicines Agency, Poster, National, CIRM, Mortality, Therapy, MS, HGF, FDA, Exosome, Multiple sclerosis, Orphan drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Food, Phrase, Hepatocyte growth factor, Amyotrophic lateral sclerosis, Company, MSC, Annual report, Brainstorm, California, LIF, AREG, Regenerative medicine, Safety, NASDAQ, Leukemia inhibitory factor, Research, BALF, TSG-6, Pharmaceutical industry, Medical imaging, Vaccine

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.